Monograph Details
|
|
Central Nervous System
> ADHD/narcolepsy
|
|
RITALIN LA |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
CII |
| Pharmacological Class |
|
Stimulant. |
| Generic Name |
|
Methylphenidate HCl 10mg, 20mg, 30mg, 40mg; ext-rel caps (one-half as immediate-release + one-half as enteric-coated, delayed-release beads). |
| Also |
• RITALIN
• RITALIN-SR
|
| Indications |
|
Attention deficit hyperactivity disorder. |
| Adults and Children |
|
Swallow whole or sprinkle contents onto applesauce (swallow immediately); do not crush, chew, or divide beads. <6yrs: not recommended. ≥6yrs: initially 20mg once daily in the AM, may increase by 10mg weekly; max 60mg/day. Switching from methylphenidate immediate-release (IR) or SR: give total daily dose of IR or SR once daily in the AM. |
| Contraindications |
|
Marked anxiety, tension, agitation. Glaucoma. History of tics or Tourette's syndrome in patient or family. During or within 14 days of MAOIs. |
| Precautions |
|
Discontinue if seizures or agitation occur. Reduce dose or discontinue if paradoxical worsening of symptoms occurs. Reassess periodically. Reevaluate therapy at puberty. Hypertension. Psychosis. Seizure disorders. Depression. Normal fatigue states. Emotionally unstable (eg, drug or alcohol abusers). May exacerbate behavior disturbances, thought disorders. Monitor growth, BP, CBC, differential, platelet counts. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
See Contraindications. Caution with pressor agents, α2-agonists (eg, clonidine). May increase levels of anticonvulsants, oral anticoagulants, tricyclics, phenylbutazone. Antagonizes guanethidine, other antihypertensives. Drugs that affect GI pH may affect release of methylphenidate from caps. |
| Adverse Reactions |
|
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache, dyskinesias, hypertension, tachycardia, arrhythmias, Tourette's syndrome, toxic psychosis, seizures, blood dyscrasias, rash, visual disturbances. |
| How Supplied |
|
All—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
